Skip Navigation LinksHome > July 2009 - Volume 27 - Issue 7 > Metabolic syndrome, insulin resistance and oxidative stress:...
Journal of Hypertension:
doi: 10.1097/HJH.0b013e32832d1f9e
Editorial commentaries

Metabolic syndrome, insulin resistance and oxidative stress: adding insights to improve cardiovascular prevention

Amiri, Farhad

Free Access
Article Outline
Collapse Box

Author Information

Acasti Pharma Inc., Montreal, Quebec, Canada

Received 5 April, 2009

Accepted 20 April, 2009

Correspondence to Farhad Amiri, PhD, Acasti Pharma Inc., 2901 Rachel E, Suite 11, Montreal, QC H1W 4A4, Canada Tel: +1 514 394 7974; fax: +1 514 527 5165; e-mail: farhad_amiri@yahoo.ca

The metabolic syndrome (MetS) is currently defined as a constellation of cardiovascular risk factors of metabolic origin that promote the development of atherosclerotic cardiovascular disease (CVD) and type 2 diabetes [1]. In the past few years, several clinical and biochemical criteria have been established in order to identify MetS patients, the most widely accepted being: visceral obesity (defined as increased waist circumference), atherogenic dyslipidemia [defined as elevated serum triglycerides and apolipoprotein B (apoB)], an increased number of small low-density lipoprotein (LDL) particles and a reduced level of high-density lipoprotein (HDL) cholesterol, increased blood pressure (BP) and increased plasma glucose [2,3]. Differences among the available guidelines are related to the criteria considered, the number of criteria that need to be fulfilled and the cut-off to define some of the criteria such as waist circumference, lipid and glucose levels and BP.

However, the definition of MetS is still a matter of great debate in clinical practice [4,5]. The main issue for clinicians and scientists is to identify a clinical condition in which metabolic risk factors cluster together rather than to simply associate. In this sense, the following two points need to be better clarified: whether the MetS is predictive of CVD, beyond the additive effects of its individual components, and whether there is a common underlying pathological process that links all the metabolic factors. With respect to the first, some clinical studies and recent meta-analysis have examined the association of the MetS with CVD and found a strong consistent relationship that remains even after adjusting for the individual cardiovascular risk factors [6–9]. Conversely, other studies [10–13] have shown that the increased mortality and/or atherosclerotic CVD associated with the MetS positively correlate with the number of criteria fulfilled and were further increased by the association with additional risk factors, such as cigarette smoking or elevated LDL cholesterol, suggesting that the cardiovascular risk is additive. As for the pathophysiology of the MetS, the most unifying hypothesis is insulin resistance that is defined as the reduction in tissue insulin-mediated glucose uptake. However, both insulin resistance and hyperinsulinemia do not appear as diagnostic criteria in most guidelines used to define MetS, mostly because of the difficulty and expensiveness of measuring them routinely in clinical practice. In this sense, surrogate markers of insulin resistance have been adopted, such as visceral obesity (assessed by waist circumference measurement), but they may not be perfectly related to insulin resistance and may not have the same diagnostic and prognostic value [14,15]. Thus, further studies are needed to improve the predictive power of the MetS in order to provide new diagnostic and prognostic tools to better identify and stratify patients affected by metabolic risk factors.

To better understand the MetS, there is a growing scientific and clinical interest around the so-called underlying risk factors, when taken together with the metabolic risk factors discussed above, which have been shown to contribute to create a proinflammatory and prothrombotic state commonly found in MetS patients. The role of these factors in the diagnosis and prognosis of the MetS is still a matter of debate, and even though their possible clinical application looks interesting, further investigation is needed to better understand whether they have a prognostic value and may represent potential pharmacological targets for MetS patients.

Among the risk factors, oxidative stress, as marker of endothelial dysfunction and inflammation, might be promising. Oxidative stress is well known to play a key role in atherosclerosis, hypertension and cardiovascular complications. A large body of evidence suggests that oxidative stress is increased in MetS, as well as in obesity and diabetes [16]. In insulin resistance patients, increased production of reactive oxygen species (ROS) and elevated oxidation of lipids products, DNA and proteins have been reported in plasma, urine and different tissues, suggesting both systemic and local oxidative stress that seems to be positively correlated to increased plasma insulin.

The NAD(P)H oxidase has been shown to be the major source of ROS production in pathological conditions related to insulin resistance and hyperinsulinemia and has been suggested to be the most important enzyme in the cardiovascular system [17,18]. In its activated form, the enzyme is a complex of membrane-associated (gp91phox and p22phox) and cytosolic (p47phox, p67phox and p40phox) subunits and includes an electron transport chain that transfers electrons from a donor, the cytosolic NAD(P)H, to an acceptor, oxygen, which also generates superoxide (O2) as a by-product. NAD(P)H was first discovered in phagocytic cells, in which it plays a crucial role in the oxidative burst, an important component of microbicidal effector cell function. More recently, NAD(P)H oxidase subunits have been shown to be expressed in different cell types, such as adipocytes, inflammatory, skeletal and cardiac muscle cells and fibroblasts [19,20], all of which contribute to enhanced ROS production in conditions related to insulin resistance and hyperinsulinemia. For instance, NAD(P)H oxidase has been shown to play a role in O2 production in experimental and human atherosclerosis through infiltrated inflammatory cells [21]. In asymptomatic patients, phagocytic NAD(P)H oxidase activity correlates with carotid intima media thickness, a marker of atherosclerosis [22], and with plasma levels of matrix metalloproteinase-9 (MMP-9), an independent biomarker of cardiovascular risk [23]. Moreover, NAD(P)H oxidase-dependent O2 production has been suggested to be not only a marker, but also a mediator of atherosclerotic CVD in different experimental models of obesity, diabetes and insulin resistance [24–26]. Thus, it is possible to speculate that increased oxidative stress associated with insulin resistance may be responsible, at least in part, for the development of atherosclerotic complication in obese, diabetic and MetS patients. However, further clinical studies are needed to clarify whether antioxidant therapies may be clinically useful for the prevention of atherosclerotic cardiovascular complications in insulin resistance patients.

Back to Top | Article Outline

Metabolic syndrome, insulin resistance and oxidative stress: adding diagnostic and prognostic insights

In the current issue of the journal, Fortuño et al. [27] provide new insights into the complex relationships between MetS, insulin resistance and oxidative stress. The authors evaluated 125 MetS patients in whom the diagnosis of MetS was established according to current American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement guidelines [3], including at least three criteria among the following: visceral obesity, hypertriglyceridemia, low HDL cholesterol, high BP or use of antihypertensive medication and high fasting glucose or use of glucose-lowering treatment. MetS patients were further stratified and divided into two groups, according to the presence or absence of insulin resistance (defined by the homeostatic model assessment index), and classified as either insulin resistance or insulin-sensitive patients. Fortuño et al. [27] have showed a correlation between plasma insulin levels and peripheral blood mononuclear cell (PBMC) O2 production and systemic oxidative stress, suggesting a key role for insulin in the regulation of oxidative stress. These data were further supported by the in-vitro findings demonstrating the ability of insulin to upregulate p22phox subunit mRNA in PBMC and macrophages. In addition to showing that insulin resistance is a major determinant of oxidative stress in MetS, the authors suggested that the association with insulin resistance and increased oxidative stress may increase the atherosclerotic cardiovascular risk in MetS patients, as shown by increased levels of MMP-9. Thus, the study of Fortuño et al. [27] highlights the prognostic value of plasma insulin and oxidative stress in MetS patients, and suggests that their measurement may represent an interesting and informative clinical tool in order to better define the cardiovascular risk in MetS.

Back to Top | Article Outline

Balancing study's strengths and limitations

The study by Fortuño et al. [27] is a very good example of translational science, in which the authors have attempted to integrate basic science experiments in a clinical setting. In their study, the authors have tried to elucidate the relationship between oxidative stress, insulin resistance and cardiovascular risk in patients affected by MetS. In particular, they have identified a subgroup of MetS patients with insulin resistance that appear to have increased oxidative stress compared with insulin-sensitive MetS patients, suggesting a role of insulin on ROS production. However, insulin resistance MetS patients displayed significantly higher BMI and waist circumference compared with insulin-sensitive patients. Thus, it is possible that increased visceral adiposity may have played the main role in insulin, oxidative stress and MMP-9 increase. Finally, the definition of cardiovascular risk adopted in their study may present some limitations, requiring further clinical investigations. In fact, even though available evidence substantiates that MMP-9 levels represent an independent risk factor for atherosclerotic CVD [28,29], long-term clinical studies considering CVD as end-point are needed to confirm the prognostic value of MMP-9 in MetS patients.

Back to Top | Article Outline

Conclusion

There is still need in clinical care for a better understanding and management of MetS patients. Thus, translational studies that investigate diagnostic and prognostic mechanisms are interesting and clinically relevant in order to optimize the predictive value of the MetS in CVD prevention. Adding insights on the proinflammatory, prooxidant and prothrombotic risk factors such as O2 production, NAD(P)H oxidase activation and MMP-9 expression, that are commonly found in MetS patients, seems interesting and challenging and may lead to future clinical applications. However, further investigation is needed to better understand whether these underlying risk factors have diagnostic and prognostic value and whether their use is routinely feasible in clinical practice and may represent potential pharmacological targets for MetS patients.

Back to Top | Article Outline

References

1 Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program: Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30:8–13.

2 Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26:1891–1900.

3 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735–2752.

4 Beaser RS, Levy P. Metabolic syndrome: a work in progress, but a useful construct. Circulation 2007; 115:1812–1818.

5 Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007; 115:1806–1810.

6 Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119:812–819.

7 Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403–414.

8 Inchiostro S, Fadini GP, de Kreutzenberg SV, Citroni N, Avogaro A. Is the metabolic syndrome a cardiovascular risk factor beyond its specific components? J Am Coll Cardiol 2007; 49:2465–2466.

9 Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008; 26:1602–1611.

10 Eberly LE, Prineas R, Cohen JD, Vazquez G, Zhi X, Neaton JD, Kuller LH. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006; 29:123–130.

11 Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640–1649.

12 Kragelund C, Omland T. A farewell to body-mass index? Lancet 2005; 366:1589–1591.

13 Solbu MD, Kronborg J, Jenssen TG, Njolstad I, Lochen ML, Mathiesen EB, et al. Albuminuria, metabolic syndrome and the risk of mortality and cardiovascular events. Atherosclerosis 2008. [Epub ahead of print]. doi: 10.1016/j.atherosclerosis.2008.11.002.

14 Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006; 29:1689–1692.

15 Grundy SM. What is the contribution of obesity to the metabolic syndrome? Endocrinol Metab Clin North Am 2004; 33:267–282.

16 Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 2009; 89:27–71.

17 Touyz RM. Apocynin, NADPH oxidase, and vascular cells: a complex matter. Hypertension 2008; 51:172–174.

18 Schiffrin EL. Oxidative stress, nitric oxide synthase, and superoxide dismutase: a matter of imbalance underlies endothelial dysfunction in the human coronary circulation. Hypertension 2008; 51:31–32.

19 Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003; 41:2164–2171.

20 Fortuno A, San JG, Moreno MU, Beloqui O, Diez J, Zalba G. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 2006; 55:209–215.

21 Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105:1429–1435.

22 Zalba G, Beloqui O, San JG, Moreno MU, Fortuno A, Diez J. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005; 25:1452–1457.

23 Zalba G, Fortuno A, Orbe J, San JG, Moreno MU, Belzunce M, et al. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:587–593.

24 Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105:1656–1662.

25 Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, Cristol JP, et al. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 2005; 179:43–49.

26 Sonta T, Inoguchi T, Tsubouchi H, Sekiguchi N, Kobayashi K, Matsumoto S, et al. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic Biol Med 2004; 37:115–123.

27 Fortuño A, Bidegain J, San José G, Robador PA, Landecho MF, Beloqui O, et al. Insulin resistance determines phagocytic NADPH oxidase overactivity in metabolic syndrome patients. J Hypertens 2009; 27:1420–1430.

28 Zalba G, Fortuno A, Orbe J, San JG, Moreno MU, Belzunce M, et al. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:587–593.

29 Zalba G, Beloqui O, San JG, Moreno MU, Fortuno A, Diez J. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005; 25:1452–1457.

© 2009 Lippincott Williams & Wilkins, Inc.

Login